dual-antiplatelet therapy

Original Contribution

Efficacy and Safety of 3 Versus 6 Months of Dual-Antiplatelet Therapy in Patients Implanted With Coroflex ISAR Stents: A Prospective, Multicenter, Randomized Clinical Trial

07/22/2022

Uram Jin, MD¹*; Kyoung-Woo Seo, MD¹*; Hyoung-Mo Yang, MD, PhD¹; Hong-Seok Lim, MD, PhD¹; Byoung-Joo Choi, MD¹; So-Yeon Choi, MD, PhD¹; Joon-Han Shin, MD¹; Seung-Jea Tahk, MD, PhD¹; Sang-Yong Yoo, MD¹; Seung Woon Rha, MD, PhD³; Woo-Young Chung, MD, PhD⁴; Chi-Hoon Kim, MD⁵; Ki-Bum Won, MD⁶; Wook Bum Pyun, MD, PhD⁷; Jae Sik Jang, MD, PhD⁸; Sung Yun Lee, MD⁹; Young Joon Hong, MD¹⁰; Moo Hyun Kim, MD, PhD¹¹; Soon Jun Hong, MD¹²; Yun-Seok Choi, MD¹³; Hee-Yeol Kim, MD¹⁴; Rak Kyeong Choi, MD, PhD¹⁵; Woong Chol Kang, MD, PhD¹⁶; Eun Joo Cho, MD, PhD¹³; Myeong-Ho Yoon, MD, PhD¹

Uram Jin, MD1*; Kyoung-Woo Seo, MD1*...

This study examined the efficacy and safety of 3- versus 6-month DAPT in patients implanted with Coroflex ISAR polymer-free DESs.

This study examined the efficacy...

07/22/2022

Journal of Invasive Cardiology

Evaluation of a Real-World In-Hospital Antiplatelet-Switching Strategy Following Coronary Interventions: The SWITCH Study

04/01/2021

Antoine E. Soueid, MD, PharmD, JD¹; Ibrahim Kassas, MD²; Jeffrey Rade, MD¹; Nikolaos Kakouros, MBBS, MD(Res), PhD¹

Antoine E. Soueid, MD, PharmD, JD1; ...

Newer antiplatelet therapy agents are reliable and have a fast onset of action, but have significantly higher cost, leading to compliance concerns. We adopted and evaluated an acute agent-switching strategy, using prasugrel or ticagrelor for...

Newer antiplatelet therapy...

04/01/2021

Journal of Invasive Cardiology

Original Contribution

Short Duration vs Standard Duration of Dual-Antiplatelet Therapy After Percutaneous Coronary Intervention With Second-Generation Drug-Eluting Stents – A Systematic Review, Meta-Analysis, and Meta-Regression Analysis of Randomized Controlled Trials

09/15/2016

Anthony W.A. Wassef, MD¹; Hadi Khafaji, FRCPG¹; Ishba Syed¹; Andrew T. Yan, MD¹; Jacob A. Udell, MD, MPH²; Shaun G. Goodman, MD, MSc¹; Asim N. Cheema, MD, PhD¹; Akshay Bagai, MD, MHS¹

Anthony W.A. Wassef, MD1; Hadi Khafa...

Current guidelines recommend 12 months of dual-antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation. We investigate whether the duration of DAPT can be safely shortened with use...

Current guidelines recommend 12...

09/15/2016

Journal of Invasive Cardiology